Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

What Was Tested

Researchers studied Peptides in this randomized controlled trial publication.

To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis.

Who Took Part

The study group was 504 patients.

The age groups tagged for this paper are middle-aged adults.

A total of 504 patients with SIRS and documented evidence of infection plus either hypotension or dysfunction of 2 organ systems.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Peptides and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Peptides, so expectations could not easily colour the readings.

Some patients received a placebo instead of Peptides, giving a reference point.

More than one site took part, so the patients came from several places.

A total of 47 US referral hospitals.

Concurrent therapy at the discretion of the treating physician.

What Was Measured

PubMed files the paper under topics including APACHE, Bradykinin Receptor Antagonists, Gram-Negative Bacterial Infections, Hypotension, Multiple Organ Failure, Peptides and Sepsis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Peptides in 504 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1997 (JAMA), a journal based in United States.

More context: all human trials.